Search Results

Verastem Oncology today announced that in connection with the 2024 Russell U.S. Indexes annual reconstitution, the company will be added to the Russell 3000 ® and Russell Microcap ® Indexes, effective at the open of U.S. equity markets today, Monday, July 1, 2024.

Verastem Oncology announced that its management team will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024 at 3:35 pm EDT.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced business updates and reported financial results for the first quarter ended March 31, 2024.

Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company’s clinical and medical strategy.